Olga Garbuzenko
Overview
Explore the profile of Olga Garbuzenko including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
14
Citations
363
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Romaniuk-Drapala A, Skupin-Mrugalska P, Garbuzenko O, Hatefi A, Minko T
Cancer Cell Int
. 2024 Aug;
24(1):285.
PMID: 39135053
Background: Olaparib is a PARP inhibitor inducing synthetic lethality in tumors with deficient homologous recombination (HRD) caused by BRCA1/2 mutations. The FDA has approved monotherapy for first-line platinum-sensitive, recurrent high-grade...
2.
Gu X, Majumder J, Taratula O, Kuzmov A, Garbuzenko O, Pogrebnyak N, et al.
Int J Mol Sci
. 2024 May;
25(10).
PMID: 38791582
A novel nanotechnology-based drug delivery system (DDS) targeted at pancreatic cancer cells was developed, characterized, and tested. The system consisted of liposomes as carriers, an anticancer drug (paclitaxel) as a...
3.
Rather G, Anyanwu M, Minko T, Garbuzenko O, Szekely Z, Bertino J
Cancers (Basel)
. 2021 Mar;
13(5).
PMID: 33652640
Background: We tested the antitumor effects of a modified E2F peptide substituting D-Arg for L-Arg, conjugated to penetratin (PEP) against solid tumor cell lines and the CCRF-leukemia cell line, alone...
4.
Shaik T, Rather G, Bansal N, Minko T, Garbuzenko O, Szekely Z, et al.
Oncotarget
. 2018 Oct;
9(70):33249-33257.
PMID: 30279956
E2F1-3a overexpression due to amplification or to mutation or loss of the retinoblastoma gene, induces genes involved in DNA synthesis and leads to abnormal cellular proliferation, tumor growth, and invasion....
5.
Xie X, Bansal N, Shaik T, Kerrigan J, Minko T, Garbuzenko O, et al.
Oncotarget
. 2014 Mar;
5(4):901-7.
PMID: 24658650
E2F-1, a key transcription factor necessary for cell growth, DNA repair and differentiation, is an attractive target for development of useful anticancer drugs in tumors that are E2F "oncogene addicted"....
6.
Xie X, Kerrigan J, Minko T, Garbuzenko O, Lee K, Scarborough A, et al.
Cancer Biol Ther
. 2013 Jun;
14(8):742-51.
PMID: 23792570
E2F-1, a key transcription factor necessary for cell growth, DNA repair, and differentiation, is an attractive target for development of anticancer drugs in tumors that are E2F "oncogene addicted". We...
7.
Szebeni J, Bedocs P, Rozsnyay Z, Weiszhar Z, Urbanics R, Rosivall L, et al.
Nanomedicine
. 2011 Jun;
8(2):176-84.
PMID: 21704590
From The Clinical Editor: The authors studied complement activation-related pseudoallergy (CARPA) in a porcine model and demonstrate that high negative surface charge and drug effects leading to distortion of liposome...
8.
Betigeri S, Zhang M, Garbuzenko O, Minko T
Drug Deliv Transl Res
. 2011 Apr;
1(1):13-24.
PMID: 21461383
Many pathological conditions and environmental impacts lead to the development of severe tissue hypoxia that aggravates the primary disorder, provokes cell death, and limits the patient's recovery. We hypothesized that...
9.
Tumor targeted quantum dot-mucin 1 aptamer-doxorubicin conjugate for imaging and treatment of cancer
Savla R, Taratula O, Garbuzenko O, Minko T
J Control Release
. 2011 Feb;
153(1):16-22.
PMID: 21342659
In this study, we report the design and delivery of a tumor-targeted, pH-responsive quantum dot-mucin1 aptamer-doxorubicin (QD-MUC1-DOX) conjugate for the chemotherapy of ovarian cancer. To achieve active cancer targeting, QD...
10.
Taratula O, Garbuzenko O, Savla R, Wang Y, He H, Minko T
Curr Drug Deliv
. 2010 Nov;
8(1):59-69.
PMID: 21034421
The ability of Superparamagnetic Iron Oxide (SPIO) nanoparticles and Poly(Propyleneimine) generation 5 dendrimers (PPI G5) to cooperatively provoke siRNA complexation was investigated in order to develop a targeted, multifunctional siRNA...